Relationship Between Cisplatin Administration and the Development of Ototoxicity

Rademaker-Lakhai, Jeany M.; Crul, Mirjam; Zuur, L.; Baas, Paul; Beijnen, Jos H.; Simis, Yvonne J.; Zandwijk, Nico van; Schellens, Jan H.M.

doi:10.1200/jco.2006.10.077

Cited by 150 publications

(103 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ototoxicity may ensue when the drug is given at a cumulative dose over 360mg/m 2 (Brock et al 3 ; Pedalini et al 4 , Simon et al 5 , Knoll et al 6 ). Cisplatin ototoxicity is the result of cochlear injury, initially in the vascular striae and the outer hair cells of the basal gyrus, which result in hearing loss at high frequencies (Rademaker et al 7 ; Rybak et al 8 ). Continued use of the drug may result in hearing loss at low frequencies (Pedalini et al 4 , Zuur et al 9 ).…”

Section: Introductionmentioning

confidence: 99%

Report on hearing loss in oncology

Schultz¹,

Goffi-Gómez²,

Liberman³

et al. 2009

Braz. j. otorhinolaryngol. (Impr.)

View full text Add to dashboard Cite

Ci splatin is used frequently as an antineoplastic drug in the treatment of many different cancers. However, when used in doses over 360mg/m 2 , ototoxicity may ensue, resulting in loss of hearing. Criteria for identifying and quantifying hearing loss have been devised. Aim: To describe the features of different hearing loss classification systems and to identify their implications and use in oncologic patients. Method: Hearing loss was classified in 31 patients before and after chemotherapy, according to different criteria, assessing the sensitivity and specificity of each classification system. Results: Hearing loss results were highly variable (ranging from 29% to 61%). Only 4 of 31 subjects with post-therapy hearing loss were identified by all the methods. A few subjects with hearing loss were classified as normal hearing in some of the criteria. A normal PTA was found in 18 of 31 subjects in the post-treatment evaluation. Conclusion: None of the criteria assesses the complaints of patients. The criteria described in this study were inadequate to identify hearing loss following chemotherapy, requiring additional information for physicians to better understand the hearing losses and their implications for the quality of life of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Report on hearing loss in oncology

Schultz¹,

Goffi-Gómez²,

Liberman³

et al. 2009

Braz. j. otorhinolaryngol. (Impr.)

View full text Add to dashboard Cite

show abstract

“…4 Cisplatin and related agents are absorbed by the cochlear hair cells and result in ototoxicity through the production of reactive oxygen species. 5 There have been reports of vincristine, a vinca alkaloid to produce similar ototoxic reactions.…”

Section: Discussionmentioning

confidence: 99%

Sudden hearing loss in a patient of Hodgkin's lymphoma following vinblastine chemotherapy: a rare case report and review of the literature

Kapoor

Narayan

Nirban

et al. 2014

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

“…Second, auditory disorders are a problem associated with 3-weekly CDDP þ RT, and weekly CDDP þ RT is superior to the former due to the lower likelihood of neurotoxicity. In particular, CDDP-related auditory disorder is a dose-limiting toxicity; it occurs dose-dependently and is irreversible in most cases (15)(16)(17)(18). In fact, in the RTOG95-01 study, the incidence of neurotoxicity including Grade 3 or more auditory disorders was 10% after 3-weekly CDDP þ RT for head and neck cancer (1).…”

Section: Introductionmentioning

confidence: 99%

Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008)

Kunieda

Kiyota

Tahara

et al. 2014

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

A randomized Phase II/III study was launched in Japan to evaluate the non-inferiority of concurrent chemoradiotherapy with weekly cisplatin (40 mg/m 2 ) compared with concurrent chemoradiotherapy with 3-weekly cisplatin (100 mg/m 2 ) for post-operative high-risk patients with locally advanced squamous cell carcinoma of head and neck. This study began in October 2012, and a total of 260 patients will be accrued from 18 institutions within 5 years. The primary endpoint of the Phase II part is proportion of treatment completion and that of the Phase III part is overall survival. The secondary endpoints are relapse-free survival, local relapse-free survival, nutrition-support-free survival, non-hospitalized treatment period during permissible treatment period and adverse events. This trial was registered at the UMIN Clinical Trials Registry as UMIN 000009125 [http://www.umin.ac.jp/ctr/].

show abstract

Relationship Between Cisplatin Administration and the Development of Ototoxicity

Abstract: Hearing loss after cisplatin therapy occurs mainly at high frequencies and at cisplatin dosages more than 60 mg/m2. It is more pronounced when cisplatin is given once every 2 weeks.

Cited by 150 publications

References 16 publications

Report on hearing loss in oncology

Report on hearing loss in oncology

Sudden hearing loss in a patient of Hodgkin's lymphoma following vinblastine chemotherapy: a rare case report and review of the literature

Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008)

Contact Info

Product

Resources

About